Cellectar Biosciences, Inc. (CLRB)
USD 0.25
(-5.11%)
USD 0.25
(-5.11%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.37 Million | -25.22 Million | -22.56 Million | -13.93 Million | -11.69 Million | -11.44 Million |
| Net Income | -37.98 Million | -28.6 Million | -24.12 Million | -15.09 Million | -14.09 Million | -13.23 Million |
| Depreciation & Amortization | 192.37 Thousand | 148.43 Thousand | 149.91 Thousand | 141.45 Thousand | 132.79 Thousand | 82.26 Thousand |
| Deferred income taxes | -39.08 Million | - | 2937.00 | -185.28 Thousand | -43 Thousand | - |
| Stock-based compensation | 2410.29 | 1452.96 | 1124.19 | 467.54 | 866.79 | 721.2 Thousand |
| Change in working capital | 3.47 Million | 1.68 Million | 198.76 Thousand | 671.23 Thousand | 1.38 Million | -569.05 Thousand |
| Other non-cash items | 38.6 Million | 93.81 Thousand | 77.72 Thousand | 66.47 Thousand | 56.56 Thousand | 1.56 Million |
| Investing Cash Flow | -864.03 Thousand | -225.97 Thousand | -141.36 Thousand | -62.35 Thousand | -24.54 Thousand | -329.99 Thousand |
| Investments in PPE | -864.03 Thousand | -225.97 Thousand | -141.36 Thousand | -62.35 Thousand | -24.54 Thousand | -384.99 Thousand |
| Acquisitions | - | - | - | - | - | 55 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | 55 Thousand |
| Financing Cash Flow | 22.93 Million | 9.61 Million | 1.24 Million | 60.54 Million | 9.02 Million | 15.02 Million |
| Debt repayment | - | - | - | -184 Thousand | -2213.00 | -3036.00 |
| Dividends payments | - | - | - | - | - | -2.24 Million |
| Common Stock Repurchased | - | - | - | - | - | 8.19 Million |
| Common Stock Issuance | 22.93 Million | 9.61 Million | 34.87 Thousand | 59.71 Million | 9.02 Million | 9.07 Million |
| Other Financing Activities | 789.64 Thousand | 9610.65 | 1.21 Million | 1.01 Million | 9022.36 | -2.24 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 3.7 Million | 1.62 Million | 411.71 Thousand | 780.6 Thousand | 1.12 Million | -258.79 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -224.39 Thousand | 60.2 Thousand | -212.95 Thousand | -109.36 Thousand | 265.99 Thousand | -310.25 Thousand |
| Cash at beginning of period | 19.86 Million | 35.7 Million | 57.16 Million | 10.61 Million | 13.31 Million | 10.06 Million |
| Cash at end of period | 9.56 Million | 19.86 Million | 35.7 Million | 57.16 Million | 10.61 Million | 13.31 Million |
| Capital Expenditure | -864.03 Thousand | -225.97 Thousand | -141.36 Thousand | -62.35 Thousand | -24.54 Thousand | -384.99 Thousand |
| Effect of forex changes on cash | 3 Million | - | - | - | - | - |
| Net cash flow / Change in cash | -10.3 Million | -15.83 Million | -21.46 Million | 46.55 Million | -2.69 Million | 3.24 Million |
| Free Cash Flow | -33.24 Million | -25.44 Million | -22.71 Million | -13.99 Million | -11.71 Million | -11.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.97 Million | -21.58 Million | -37.98 Million | -7.44 Million | -13.73 Million | -8.22 Million |
| Depreciation & Amortization | 66.02 Thousand | 88.49 Thousand | 192.37 Thousand | 69.96 Thousand | 41.2 Thousand | 38.65 Thousand |
| Deferred income taxes | - | - | -39.08 Million | -4.37 Million | 4.37 Million | - |
| Stock-based compensation | 799.25 Thousand | 454.36 | 2410.29 | 1084.45 | 497.88 | 419.76 |
| Change in working capital | -1.64 Million | -2.23 Million | 3.47 Million | 1.58 Million | 740.64 Thousand | 218.89 Thousand |
| Other non-cash items | -7.37 Million | 12.33 Million | 38.6 Million | -514.71 Thousand | 14.73 Thousand | 14.2 Thousand |
| Investing Cash Flow | -21.27 Thousand | -21.63 Thousand | -864.03 Thousand | -266.75 Thousand | -597.28 Thousand | - |
| Investments in PPE | -21.27 Thousand | -21.63 Thousand | -864.03 Thousand | -266.75 Thousand | -597.28 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.00 | 43.84 Million | 22.93 Million | 441 Thousand | 22.49 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -21.7 Thousand | - | - |
| Common Stock Issuance | -43.84 Million | 43.84 Million | 22.93 Million | 441 Thousand | 22.49 Million | - |
| Other Financing Activities | 1.00 | 43.84 Thousand | 789.64 Thousand | 789.64 Thousand | 22.49 Thousand | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -930.74 Thousand | -1.78 Million | 3.7 Million | 1.36 Million | 1.42 Million | -512.87 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1.64 Million | -453.59 Thousand | -224.39 Thousand | 219.21 Thousand | -682.27 Thousand | 731.76 Thousand |
| Cash at beginning of period | 40.03 Million | 9.56 Million | 19.86 Million | 18.98 Million | 5.15 Million | 12.68 Million |
| Cash at end of period | 25.86 Million | 40.03 Million | 9.56 Million | 9.56 Million | 18.98 Million | 5.15 Million |
| Capital Expenditure | -21.27 Thousand | -21.63 Thousand | -864.03 Thousand | -266.75 Thousand | -597.28 Thousand | - |
| Effect of forex changes on cash | - | - | 3 Million | - | - | - |
| Net cash flow / Change in cash | -14.16 Million | 30.46 Million | -10.3 Million | -9.42 Million | 13.83 Million | -7.52 Million |
| Free Cash Flow | -14.16 Million | -13.38 Million | -33.24 Million | -9.86 Million | -8.66 Million | -7.52 Million |
KDNC
KCDGROUP
688079
178920
SUNITATOOL
SAF